ADMA Biologics (ADMA) vs BioCryst Pharmaceuticals (BCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed ADMA Biologics (ADMA) over the past year, gaining 20.9% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with -44.5% for BCRX. ADMA Biologics is the larger company by market cap ($2.27 billion vs $2.10 billion), about 1.1 times the size.
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (8.7x vs 10.8x for ADMA Biologics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | BCRX |
|---|---|---|
| Share price | $10.16 | $8.21 |
| Market cap | $2.27B | $2.10B |
| 1-day change | +0.15% | -2.26% |
| YTD return | -44.41% | +7.69% |
| 1-year return | -27.52% | +20.86% |
| 5-year return | +821.82% | -44.48% |
| P/E ratio (TTM) | 14.51 | — |
| Forward P/E | 10.77 | 8.73 |
| EPS (TTM) | $0.70 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $11.22 |
| 52-week low | $7.21 | $6.00 |
| Distance from 52-week high | -50.36% | -26.83% |
| Analyst consensus | none | buy |
| Avg. price target upside | +67.41% | +152.50% |
| Average volume | 2.63M | 4.11M |
| Shares outstanding | 223.98M | 255.54M |
| Employees | 640 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed ADMA by 48.4 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
ADMA vs BCRX FAQ
Which is bigger, ADMA Biologics or BioCryst Pharmaceuticals?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.27B compared with $2.10B for BioCryst Pharmaceuticals (BCRX).
Which stock has performed better over the past year, ADMA or BCRX?
BCRX returned +20.86% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and BioCryst Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.